Celldex Therapeutics, Inc. (CLDX) | Investment Case

1. Company Snapshot

1.a. Company Description

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer.The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.

The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc.with exclusive rights to CDX-301 and CD40 ligand; and Yale University.Celldex Therapeutics, Inc.

was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Show Full description

1.b. Last Insights on CLDX

Celldex Therapeutics' recent performance has been positively driven by increased institutional investment, with American Century Companies Inc. growing its position by 24.7% during the second quarter. The company has also made progress in its pipeline, presenting data demonstrating barzolvolimab's efficacy in chronic spontaneous urticaria. Additionally, Celldex has strengthened its leadership team with the appointment of Teri Lawver as Chief Commercial Officer. These developments have likely contributed to a more favorable outlook for the biopharmaceutical company.

1.c. Company Highlights

Last Price	29.45
Change Percentage	-0.51%
Open	29.52
Previous Close	29.6
Market Cap ( Millions)	1957
Volume	1046953
Year High	29.83
Year Low	14.4
M A 50	26.02
M A 200	22.29

FCF Yield	-9.56%
Dividend Yield	0.00%
ROE	-27.62%
Debt / Equity	0.46%
Net Debt / EBIDTA	8.65%
Price To Book	2.98
Price Earnings Ratio	-9.8
Price To FCF	-10.46
Price To sales	337.92
EV / EBITDA	-8.37

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Fisher Asset Management LLC Sells 49,420 Shares of Celldex Therapeutics, Inc. $CLDX

Dec -04

Source: defenseworld.net

American Century Companies Inc. Grows Position in Celldex Therapeutics, Inc. $CLDX

Dec -03

Source: defenseworld.net

Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer

Nov -10

Source: globenewswire.com

Celldex to Present at Upcoming Investor Conferences

Nov -07

Source: globenewswire.com

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Sep -17

Source: globenewswire.com

Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep -10

Source: seekingalpha.com

Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

Sep -09

Source: globenewswire.com

Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track

Aug -21

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Novel Therapeutics

Expected Growth: 11.3%

Celldex Therapeutics' Novel Therapeutics segment growth of 11.3% is driven by increasing adoption of CDX-0158, a promising treatment for chronic refractory gout, and CDX-1140, a novel immunotherapy for various cancers. Strong clinical trial results, strategic partnerships, and expanding pipeline contribute to the segment's growth momentum.

7. Detailed Products

Glembatumumab vedotin

An antibody-drug conjugate designed to treat various types of cancer, including melanoma and breast cancer.

Varlilumab

A monoclonal antibody designed to treat various types of cancer, including melanoma, lung cancer, and kidney cancer.

CDX-0159

A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer.

CDX-1140

A monoclonal antibody designed to treat various types of cancer, including breast cancer and lung cancer.

CDX-527

A monoclonal antibody designed to treat various types of cancer, including melanoma and breast cancer.

8. Celldex Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Celldex Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and immunological disorders.

Bargaining Power Of Customers

Celldex Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

Celldex Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Celldex Therapeutics, Inc. has a high threat of new entrants due to the growing demand for cancer and immunological disorder treatments and the presence of emerging biotech companies.

Intensity Of Rivalry

Celldex Therapeutics, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.59%
Debt Cost	3.95%
Equity Weight	99.41%
Equity Cost	11.94%
WACC	11.89%
Leverage	0.59%

11. Quality Control: Celldex Therapeutics, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.6

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

Rhythm Pharma

A-Score: 4.5/10

Value: 6.0

Growth: 5.1

Quality: 3.8

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

Ionis Pharmaceuticals

A-Score: 4.2/10

Value: 6.0

Growth: 1.1

Quality: 4.5

Yield: 0.0

Momentum: 10.0

Volatility: 3.7

1-Year Total Return ->

Amicus Therapeutics

A-Score: 3.6/10

Value: 4.4

Growth: 7.6

Quality: 3.8

Yield: 0.0

Momentum: 1.0

Volatility: 5.0

1-Year Total Return ->

Celldex Therapeutics

A-Score: 3.4/10

Value: 6.6

Growth: 3.0

Quality: 5.0

Yield: 0.0

Momentum: 3.0

Volatility: 3.0

1-Year Total Return ->

Denali Therapeutics

A-Score: 3.3/10

Value: 6.8

Growth: 3.7

Quality: 6.2

Yield: 0.0

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

30.92%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

11.89%

Celldex Therapeutics, Inc. - US15117B2025

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on CLDX

1.c. Company Highlights

Fairly Valued

Stable Momentum

Medium Volatility

Earnings Beats

Revenues Miss

Average Growth

Average Quality

Average Yield

Revenues Beats

Weak Momentum

Earnings Miss

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Novel Therapeutics

Expected Growth: 11.3%

7. Detailed Products

Glembatumumab vedotin

Varlilumab

CDX-0159

CDX-1140

CDX-527

8. Celldex Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Celldex Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

29.45$

Current Price

29.45$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA